Cargando…

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, Maximilian, Hentschel, Leopold, Schuler, Markus, Müller, Theresa, Schütte, Katharina, Ko, Yon-Dschun, Schmidt-Wolf, Ingo, Jaehde, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320985/
https://www.ncbi.nlm.nih.gov/pubmed/37407982
http://dx.doi.org/10.1186/s12885-023-11115-7
_version_ 1785068544605552640
author Günther, Maximilian
Hentschel, Leopold
Schuler, Markus
Müller, Theresa
Schütte, Katharina
Ko, Yon-Dschun
Schmidt-Wolf, Ingo
Jaehde, Ulrich
author_facet Günther, Maximilian
Hentschel, Leopold
Schuler, Markus
Müller, Theresa
Schütte, Katharina
Ko, Yon-Dschun
Schmidt-Wolf, Ingo
Jaehde, Ulrich
author_sort Günther, Maximilian
collection PubMed
description BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this study was the development of disease-specific PRO-CTCAE item sets for patients with breast cancer (BC), multiple myeloma (MM), and prostate cancer (PC). METHODS: The cross-sectional survey was conducted at three German outpatient cancer centers. Prevalence and importance of the 78 PRO-CTCAE symptoms were assessed using a patient questionnaire. To select the most relevant PRO-CTCAE items for each tumor entity, symptoms were ranked based on patient answers. RESULTS: 101 patients with BC, 107 with MM, and 66 with PC participated. The final item sets contained 21 symptoms (BC) or 19 symptoms (MM and PC), respectively. Eight symptoms (fatigue, muscle pain, insomnia, joint pain, general pain, dizziness, shortness of breath, and swelling) were represented in all three item sets. Fatigue was the symptom with the highest ranking across item sets followed by insomnia. Symptoms with the highest rankings represented in only one item set were symptoms affecting the urogenital system in the PC item set, blurred vision in the BC item set, and decreased appetite in the MM item set. CONCLUSIONS: Individual PRO-CTCAE item sets for a German patient population were developed for the three tumor entities on the basis of patients’ differences in symptom profiles and perceptions. The quality and psychometric criteria of the newly compiled item sets should be evaluated in validation studies.
format Online
Article
Text
id pubmed-10320985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103209852023-07-06 Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers Günther, Maximilian Hentschel, Leopold Schuler, Markus Müller, Theresa Schütte, Katharina Ko, Yon-Dschun Schmidt-Wolf, Ingo Jaehde, Ulrich BMC Cancer Research BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this study was the development of disease-specific PRO-CTCAE item sets for patients with breast cancer (BC), multiple myeloma (MM), and prostate cancer (PC). METHODS: The cross-sectional survey was conducted at three German outpatient cancer centers. Prevalence and importance of the 78 PRO-CTCAE symptoms were assessed using a patient questionnaire. To select the most relevant PRO-CTCAE items for each tumor entity, symptoms were ranked based on patient answers. RESULTS: 101 patients with BC, 107 with MM, and 66 with PC participated. The final item sets contained 21 symptoms (BC) or 19 symptoms (MM and PC), respectively. Eight symptoms (fatigue, muscle pain, insomnia, joint pain, general pain, dizziness, shortness of breath, and swelling) were represented in all three item sets. Fatigue was the symptom with the highest ranking across item sets followed by insomnia. Symptoms with the highest rankings represented in only one item set were symptoms affecting the urogenital system in the PC item set, blurred vision in the BC item set, and decreased appetite in the MM item set. CONCLUSIONS: Individual PRO-CTCAE item sets for a German patient population were developed for the three tumor entities on the basis of patients’ differences in symptom profiles and perceptions. The quality and psychometric criteria of the newly compiled item sets should be evaluated in validation studies. BioMed Central 2023-07-05 /pmc/articles/PMC10320985/ /pubmed/37407982 http://dx.doi.org/10.1186/s12885-023-11115-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Günther, Maximilian
Hentschel, Leopold
Schuler, Markus
Müller, Theresa
Schütte, Katharina
Ko, Yon-Dschun
Schmidt-Wolf, Ingo
Jaehde, Ulrich
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title_full Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title_fullStr Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title_full_unstemmed Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title_short Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
title_sort developing tumor-specific pro-ctcae item sets: analysis of a cross-sectional survey in three german outpatient cancer centers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320985/
https://www.ncbi.nlm.nih.gov/pubmed/37407982
http://dx.doi.org/10.1186/s12885-023-11115-7
work_keys_str_mv AT gunthermaximilian developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT hentschelleopold developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT schulermarkus developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT mullertheresa developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT schuttekatharina developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT koyondschun developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT schmidtwolfingo developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters
AT jaehdeulrich developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters